GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Q1 FY27 Standalone Net Profit at Rs. 588.56 Lacs

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 06 Aug 2026, 07:59 PM IST  ·  BSE ID: 4b0be045-ce34-401a-9758-baa8ce99cc76
View Original BSE Filing (PDF)
💡
In Simple Terms
Jenburkt Pharmaceuticals announced its latest financial results, showing Rs. 3551.20 Lacs in revenue and Rs. 588.56 Lacs net profit.
🤖 AI Summary
  • Board of Directors approved standalone unaudited financial results for Q1 FY27 (quarter ended June 30, 2026).
  • Revenue from Operations for Q1 FY27 reported at Rs. 3551.20 Lacs.
  • Profit After Tax for the quarter ended June 30, 2026, was Rs. 588.56 Lacs.
  • Earnings Per Share (Basic and Diluted) for Q1 FY27 stood at Rs. 13.34.
  • The Board Meeting to approve results was held on August 6, 2026, concluding at 5:40 p.m. IST.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q1 FY27)
3551.20 Lacs
-0.04%
Total Income (Q1 FY27)
3702.52 Lacs
-1.48%
Profit before tax (Q1 FY27)
676.91 Lacs
-33.52%
Profit After Tax (Q1 FY27)
588.56 Lacs
-24.47%
Earnings Per Share (Q1 FY27)
13.34 Rs.
-24.46%
🏢 How This Affects the Company
💰
Financial Impact
The company reported a Profit After Tax of Rs. 588.56 Lacs for Q1 FY27, compared to Rs. 779.18 Lacs in Q1 FY26. Total income for the quarter was Rs. 3702.52 Lacs, a decrease from Rs. 3758.39 Lacs in the prior year comparable period.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as reflected in the Q1 FY27 Profit After Tax of Rs. 588.56 Lacs and Earnings Per Share of Rs. 13.34.
🔍
Management Signal
The Board's approval and disclosure of the Q1 FY27 unaudited financial results signals routine compliance with regulatory requirements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q2 FY27 results — monitor revenue and profit trends.
Any further disclosures regarding operational expenditure management.
Updates on the impact of Labour Codes on future financial periods.
MEDIUM RISK Decline in Q1 FY27 revenue and profit compared to Q1 FY26 raises moderate concerns.
💡 Investor Takeaway
Jenburkt Pharmaceuticals reported Q1 FY27 Revenue from Operations at Rs. 3551.20 Lacs and Profit After Tax at Rs. 588.56 Lacs. This reflects a decline from Q1 FY26 figures of Rs. 3552.68 Lacs and Rs. 779.18 Lacs, respectively.
⚖️ Strengths & Concerns

✅ Positives

  • Company reported a Profit After Tax of Rs. 588.56 Lacs for the quarter ended June 30, 2026.
  • Standalone total income reached Rs. 3702.52 Lacs for Q1 FY27.

⚠️ Concerns

  • Revenue from Operations for Q1 FY27 decreased to Rs. 3551.20 Lacs from Rs. 3552.68 Lacs in Q1 FY26.
  • Profit After Tax for Q1 FY27 was Rs. 588.56 Lacs, a decline from Rs. 779.18 Lacs in Q1 FY26.
📅 Company Track Record
Jenburkt Pharmaceuticals previously intimated a Board meeting for Q4 FY26 results and dividend decision on April 28, 2026, which was held on May 5, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Jenburkt Pharmaceuticals' standalone Revenue from Operations for the quarter ended June 30, 2026?
Jenburkt Pharmaceuticals reported standalone Revenue from Operations of Rs. 3551.20 Lacs for the quarter ended June 30, 2026.
What was the Profit After Tax for Jenburkt Pharmaceuticals in Q1 FY27?
The Profit After Tax for Jenburkt Pharmaceuticals for the quarter ended June 30, 2026 (Q1 FY27) was Rs. 588.56 Lacs.
How does Jenburkt Pharmaceuticals' Q1 FY27 Profit After Tax compare to Q1 FY26?
Jenburkt Pharmaceuticals' Profit After Tax for Q1 FY27 was Rs. 588.56 Lacs, a decrease from Rs. 779.18 Lacs reported in the comparable Q1 FY26 period.
What were the Earnings Per Share (EPS) for Jenburkt Pharmaceuticals for the quarter ended June 30, 2026?
The Basic and Diluted Earnings Per Share for Jenburkt Pharmaceuticals for Q1 FY27 was Rs. 13.34.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.